Graham Warren, MD, PhD
Profile
Areas of Expertise:
Gastrointestinal cancer
Head and neck cancer
Lung cancer
General cancer
Esophageal cancer
Pancreatic cancer
Hepatobiliary cancer
Colon Cancer
Rectal Cancer
Anal Cancer
Research
Research Interests:
Translational assessment of cancer treatment response
Functional and molecular characterization of tumor response to chemotherapy and radiotherapy
Evaluation of tumor sensitization and protection to therapy
Assessment of the tumor stromal interface and response to treatment
Development of treatment response modifiers and predictors of therapeutic response and outcome
Validation of mathematically derived signal transduction interactions
Biologic and physical modeling of mixed radioisotope brachytherapy sources
Fiducial markers for tumor tracking
Selected Publications:
Platek ME, McCloskey SA, Cruz M, Burke MA, Reid ME, Wilding GE, Rigual NR, Popat SR, Warren GW, Sullivan M, Hicks EL, Loree TR, Singh AK Quantification of the Effect of Treatment Duration on Local Regional Failure after Definitive Concurrent Chemotherapy and Intensity Modulated Radiation Therapy for Squamous Cell Carcinoma of the Head and Neck Submitted, Head Neck
Warren GW, Kasza K, Reid M, Cummings KM, Marshall JR Smoking at Diagnosis and Survival in Cancer Patients Submitted, J Natl Cancer Institute
Patil SS, Schmidtt JD, May KS, Hales LD, Hackett RA, Van-Benthuysen LT, Malik NK, Yang GY, Warren GW A Comparison of VMAT, IMRT, and 3DCRT in the Treatment Planning of Patients with Distal Esophageal Cancer Submitted, Pract Radiat Oncol
Malik N, May KS, Chandrasekhar R, Ma WW, Flaherty L, Iyer R, Gibbs J, Kuvshinoff B, Wilding
G, Warren G, Yang G Treatment of Locally Advanced Unresectable Pancreatic Cancer:
A 10-Year Experience Submitted, Int J Radiat Oncol Biol Phys
Warren GW, Arnold SM, Valentino JP, Gal TJ, Hyland AJ, Singh AK, Rangnekar VM, Cummings KM, Marshall JR, Kudrimoti MR Accuracy of Self-Reported Tobacco Assessments in a Head and Neck Cancer Treatment Population. Accepted with Revision, Radiother Oncol
Martin KL, Gomez J, Nazareth, DP, Warren GW, Singh AK Quantification of Incidental Mediastinal and Hilar Irraditiation Delivered During Definitive Stereotactic Body Radiation Therapy for Peripheral Non-Small Cell Lung Cancer Med Dosim Oct 4, 2011
Platek ME, Reid ME, Wilding GE, Jaggernauth W, Rigual NR, Hicks WL Jr, Popat SR, Warren GW, Sullivan M, Thorstad WL, Khan MK, Loree TR, Singh AK Pretreatment nutritional status and locoregional failure of patients with head and neck cancer undergoing definitive concurrent chemoradiation therapy. Head Neck 33:1561-8, 2011
Gosselin MH, Mahoney MC, Cummings KM, Loree TL, Sullivan M, King BA, Warren G, Hyland A Evaluation of an intervention to enhance the delivery of smoking cessation services to patients with cancer. J Cancer Educ DOI 10.1007/s13187-011-0221-3, 2011
Platek ME, Merzianu M, Mashtare TL, Popat SR, Loree T, Hicks W, Warren GW, Rigual N,
Singh AK Improved Survival Following Surgery and Radiation for Olfactory
Neuroblastoma: Analysis of the SEER Database Radiat Oncol 6:4, 2011
Esophageal and Esophagogastric Junction Cancers Panel Esophageal and Esophagogastric
Junction Cancers Version 1.2011, J Nat Comp Care Network, www.nccn.org, 2011
Gastric Cancer Panel Gastric Cancer. NCCN Clinical Practice Guidelines in Oncology Version
1.2011 J Nat Comp Care Network, www.nccn.org, 2011
Platek ME, Reid ME, Wilding GE, Wainwright J, Rigual NR, Hicks WL, Popat SR, Warren GW,
Sullivan M, Thorstad WL, Khan MK, Loree TR, Singh AK. Pretreatment nutritional
status and locoregional failure of head and neck cancer patients with head and neck cancer
undergoing definitive concurrent chemoradiation therapy Head and Neck DOI: 10.1002/hed.21640, 2010.
Sun Y, St. Clair DK, Fang F, Warren GW, Rangnekar VM, Crooks PA, St. Clair WH The
Radiosensitization Effect of Parthenolide in Prostate Cancer Cells is Mediated by NF-ĸB
Inhibition and Enhanced by the Presence of PTEN. Mol Cancer Therap 6: 2477-84, 2007.
Grimes KR, Warren GW, Fang F, Xu Y, St. Clair WH Cyclooxygenase-2 Inhibitor, Nimesulide,
Improves Radiation Treatment Against Non-small Cell Lung Cancer both In Vitro and In
Vivo. Oncol Rep 16: 771-776, 2006.
Warren GW, Grimes KR, Xu Y, St. Clair WH Selectively Enhanced Radiation Sensitivity in
Prostate Cancer Cells Associated with Proteasome Inhibition. Oncol Rep 15: 1287-1291,
2006.
Liao J, Davey DD, Warren G, Davis J, Moore AR, Samayoa LM Ultrasound-guided fine-needle
aspiration biopsy remains a valid approach in the evaluation of nonpalpable breast lesions.
Diagn Cytopathol 30: 325-331, 2004.
Warren GW, Van Ess PJ, Watson AM, Mattson MP, Blouin RA Cytochrome P450 and
antioxidant activity in interleukin-6 knockout mice after induction of the acute phase
response. J Interferon Cytokine Res 21: 821-826, 2001.
Watson AM, Warren GW, Howard G, Shedlofsky SI, Blouin RA Activities of Conjugating and
Antioxidant Enzymes Following Endotoxin Exposure. J Biochem Mol Toxicol 13: 63-69,
1999.
Blouin RA and Warren GW Pharmacokinetic Consideration in Obesity: A Minireview. J Pharm
Sci 88: 1-7, 1999.
Warren GW, Poloyac SM, Gary DS, Mattson MP, Blouin RA Hepatic Cytochrome P450
Expression in TNF (p55,p75) Receptor Double Knockout Mice Following Endotoxin
Administration. J Pharmacol Exp Therap 288: 945-950, 1999.
Roe AL, Warren G, Hou G, Howard G, Shedlofsky SI, Blouin RA The Effect of High Dose
Endotoxin on CYP3A2 in the Rat. Pharm Res 15: 1603-1608, 1998.
Grants:
PI: “A Dedicated Institutional Tobacco Cessation Service”
Roswell Park Alliance Foundation (62-1068-01)
$30,000 Accepted 8/11/11 (Funding for 8/1/11 - 7/31/11)
PI: "Critical Pathways of Tobacco Mediated Decreases in Therapeutic Response"
Roswell Park Alliance Foundation
$48,868 Accepted (Funding for 6/1/11 – 5/31/12)
PI: “Tobacco Use and Breast Cancer Prognosis: a Pilot Study”
Roswell Park Alliance Foundation
$9,022
PI: “The Acute Effects of Tobacco Products on Protein Expression in Cancer Cells:
American Cancer Society Institutional Research Grant Supplement
$6,744 (Accepted April 1, 2011, Funding for 4/1/11 – 3/31/12)
PI: “Pathways Critical to Nicotine Mediated Decreases in Cancer Therapy Response”
American Cancer Society (MRSG-11-031-01-CCE)
$729,000 (Accepted September 25, 2010, Funding for 1/1/11 – 12/31/15)
Effort: 60%
Co-I: “Development of a SPORE for Head and Neck Cancer”
National Institutes of Health (5P30 CA016056-34)
$6,000 (Funding for 7/1/10 – 6/30/11)
Marshall (PI)
PI: “Biochemically Validated Estimates of Tobacco Use in Cancer Patients”
American Cancer Society Institutional Research Grant
$10,000 (Accepted March 25, 2010, Funding for 4/1/10 – 12/31/11)
Effort: 5% (voluntary)
PI: "Pre-Clinical Studies of Nicotine in Mice"
Roswell Park Cancer Institute Animal Care and Use Committee (1163M)
Approved March 9, 2010
PI: "Nicotine in the Regulation of Lung Cancer Treatment Response"
2008 ASCO Foundation Young Investigators Award (3048104845)
$50,000 (Accepted March, 2008, Funding for 7/1/08 – 6/30/09)
Co-I and Principal Author: “Nicotine in the Regulation of Cancer Treatment Response”
University of Kentucky Institutional Animal Care and Use Committee (2008-0363)
Approved November, 2008
PI: "Nicotine and Response to In Vitro Treatment of Head/Neck and Lung Cancer Cells with
Chemotherapy, Radiotherapy, or Chemoradiotherapy"
University of Kentucky Radiation Medicine Research Fund
$10,000 (Accepted October, 2007, Funding for 7/1/07 – 6/30/08)
Co-I: "NF-kappa-B Decoy DNA: Formulation and Liver Targeting"
University of Kentucky Medical Center Research Fund
$15,000 (Funding for 7/1/00 – 6/30/01)
Other Funding:
PI: “The Role of Nicotine Assessment in Cancer Treatment Response”
National Institutes of Health, National Cancer Institute
Loan Repayment Program (XNHK7519)
$70,000 submitted 12-1-09 (Funding for 10/1/10 - 9/30/12)
PI: Faculty Research Startup
Roswell Park Cancer Institute
$720,000 (Funding for 7/1/09 - 6/30/14)
Patents:
First Inventor: “Method for Cancer Assessment”
New U.S. Provisional Patent Application No. 61/265,492
Submitted Dec. 1, 2009
Background Information
Education and Training:
College of Medicine, University of Kentucky
Graduate Center for Toxicology, University of Kentucky
2004 - 2005: Surgical Intern, Department of General Surgery, University of Kentucky
2000 - 2004: Medical Student, awarded Doctor of Medicine May 15, 2004, College of Medicine, University of Kentucky
1996 - 1999: Graduate Student, awarded Doctor of Philosophy December 17, 1999, Graduate Center for Toxicology, University of Kentucky
1999: Dissertation Title: Tumor Necrosis Factor Alpha and Interleukin-6: Regulation of Liver Enzymes During the Acute Phase Response
1998: Engineer in Training Certification: Kentucky State Board of Licensure for Professional Engineers and Land Surveyors
1990 - 1996: Undergraduate, awarded Bachelor of Science in Civil Engineering, ABET Accredited College of Engineering, University of Kentucky, Major: Civil Engineering
Residency:
Department of Radiation Medicine, University of Kentucky College of Medicine, Lexington, KY
Professional Experience:
2009 - Present: Assistant Professor of Oncology, Department of Radiation Medicine, Roswell Park Cancer Institute, Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Member, Graduate School Faculty, State University of New York (SUNY) at Buffalo
2008 - 2009: Young Investigator, American Society of Clinical Oncology
2007 - 2008: Chief Resident, Department of Radiation Medicine, University of Kentucky
2005 - 2009: Resident , Department of Radiation Medicine, University of Kentucky
Board Certification:
Radiation Oncology, American Board of Radiology
